Medical net May 16, 10,000 small and small pharmaceutical companies will lose the qualification for selling medicine! 

 

With the introduction of the two-ticket system, the concentration of circulation has increased. Hubei and guangxi has released circulation market planning respectively, said you would have a 90% market share, top drug batch, if other provinces are also a similar plan, the country is expected to more than 1 m no medicine can sell small medicine group. 

 

▍ over thousands of small and medium-sized manufacturers and only for large commercial shipping 

 

This is possible. According to media reports, in January 2017, fujian provincial health office director Zhang Xuanhua introduction, implement the "two votes" after a few years, the number of shipping enterprises in fujian province from 200 to the present 62, as much as two-thirds distribution are gone. 

 

So what do you do when you lose the market? 

 

Yesterday (14 May), in the implementation of planned blue parker "seven times seven of the President of China pharmaceutical enterprise management association (expand) the conference, and 31 Chinese medicine industry development peak BBS", from the reform of the state council to handle TiGaiSi supervision of yong-feng zhu director, made a clear explanation on this question. 

 

After zhu director, said the increase of concentration of circulation market, small and medium-sized manufacturers and can be large wholesale companies hire, the remote, and big drug delivery batch of cover less than region, between the two sides open service invoice, the ownership of the drug is not change, not to increase a make out an invoice. 

 

"This arrangement, in fact, was done before the 'two-ticket' policy was enacted," said zhu, who had researched and repeatedly demonstrated it. 

 

▍ will face the competition and the impact of third-party logistics, motion, postal... 

 

The plan is very clear, most of the circulation market is handed over to the hundred strong drug batch, small and medium medicine batch full-time for them to deliver, don't mix and sell the matter of medicine. 

 

In February 9, 2017, issued by the general office of the state council's "on further reform and improve the use policy for producing and distributing medicines of several opinions of the request:" speed up the formation of large-scale backbone enterprises as the main body, small and medium enterprises for the complementary medicine circulation network. To encourage small and medium-sized pharmaceutical circulation enterprises specialized operation, push some companies to channel distribution mode transition." 

 

At the meeting, zhu's speech, from the state council's reform office, was a clear interpretation of the details of the policy. 

 

There is no door for selling drugs, and the most powerful competitor is third-party logistics, which is targeted for delivery. In particular, the Internet has infiltrated the end of the twig, and the more ambitious logistics of the distribution of medicine, such as the prosperous, the postal service and so on. 

 

▍ small and medium-sized manufacturers don't power transformation, was suspended 

 

In comparison to third party logistics, the biggest advantage of drug companies lies in the obvious medical properties. It is clear that we have been in business for many years, in the industry, in the market, and in the medical industry. In collaboration with the drug administration, it is easy to identify with the genes that third-party logistics do not have. 

 

But you can also see that opponents are also working. By working with drug companies, the company has set up five distribution companies. The same is true of the postal service, which operates in a number of regions with a well-developed distribution network. Similarly, after the policy encouraged third party logistics, many logistics companies are eager to try. You know, drugs are just a matter of demand, and the potential for the delivery market is very clear. 

 

More important, however, is that the logistics companies, by charging a fee, will be deadly to drugmakers accustomed to charging for the price of drugs. 

 

On the one hand, there is the psychological gap between the role reversal, from the business of medicine to delivery; There is also competition for a deadly third logistics. The small and medium drug companies will not comply with the policy's positioning requirements, and the transformation of the forces will be suspended.